Real-World Single-Center Experience With 10 Cases of Generalized Pustular Psoriasis Successfully Treated With Ixekizumab

This study reported on 10 cases of generalized pustular psoriasis (GPP) treated with ixekizumab, an anti-interleukin-17 antibody. The patients, diagnosed by board-certified dermatologists, had previously undergone various treatments, including oral medications and biologics, with limited success. The mean age of patients was 65.2 years. Ixekizumab treatment led to significant improvements in Psoriasis Area and Severity Index (PASI) scores, with 100% of patients achieving a PASI 75 by week 12. The study concluded that ixekizumab was an effective treatment for GPP, regardless of genetic mutations in IL36RN and CARD14, and should be considered a treatment option for GPP patients.